肝癌免疫相关预后标志物的分析

Analysis of immune-related prognostic markers of liver cancer

目的:筛选与免疫相关的、稳定的肝癌预后标志物。方法:从癌症基因组图谱(TCGA)数据库中下载肝癌患者的相关数据,筛选出差异表达的肝癌免疫相关基因。通过对这些基因进行单因素、多因素分析,筛选肝癌预后标志物。用DAVID在线工具进行GO和KEGG富集途径分析。利用HPA数据库和GSE14520对结果进行验证。结果:本研究获得了一个由9个与肝癌免疫相关的基因(PSMD14、STC2、SPP1、ISG20L2、MAPT、NR6A1、PSME3、HSP90AA1和CSPG5)组成的肝癌预后标志物,这一标志物与肝癌患者的总生存期显著相关(P<0.001)。结论:由PSMD14、STC2、SPP1、ISG20L2、MAPT、NR6A1、PSME3、HSP90AA1和CSPG5组成的标志物可作为评估肝癌预后的分子标志物,为肝癌的有效免疫治疗策略提供了新的见解。

Aim:To mine a prognostic biomarker consisted of immune-related genes for liver cancer.Methods:We selected immune-related differentially expressed genes from gene expression data of liver cancer patients in the cancer genome atlas(TCGA)database.To excavate prognosis biomarkers,we used univariate and multivariate Cox regression analysis.Visualization andintegrated discovery(DAVID)database was used to enrich biological themes on GO terms and on the Kyoto encyclopedia of genes and genomes(KEGG)pathway maps.Human protein atlas(HPA)database and GSE14520 were utilized to testify the stable of our results.Results:In our study,we identified and validated a biomarker consisted of 9 immune-related genes(PSMD14,STC2,SPP1,ISG20L2,MAPT,NR6A1,PSME3,HSP90AA1 and CSPG5)that could be useful for outlining overall survival(OS)of patients with liver cancer(P<0.001).Conclusion:The biomarker consisted of PSMD14,STC2,SPP1,ISG20L2,MAPT,NR6A1,PSME3,HSP90AA1 and CSPG5 is significantly associated with prognosis of liver cancer.Our findings have given novel insights of new immunotherapies for liver cancer.